The neurological features of JSRD include hypotonia, ataxia, psychomotor delay, irregular breathing pattern and oculomotor apraxia and are variably associated with multiorgan involvement, mainly retinal dystrophy, nephronophthisis (NPH) and congenital liver fibrosis. JSRD are genetically heterogeneous, and all known genes encode proteins localized at or near the primary cilium[@R1]. We previously mapped the *JBTS2* (also known as *CORS2*) locus to chromosome 11p12-q13.3 in a large Sicilian family and in three consanguineous pedigrees from the Middle East[@R2]-[@R3]. Aligning the two datasets suggested a minimal candidate interval between D11S1344 and D11S1883 (46.123-63.130 Mb)[@R4] ([Fig. 1a](#F1){ref-type="fig"}**)**.

Overlapping with JSRD is MKS, characterized by occipital encephalocele and other posterior fossa defects, cystic dysplastic kidneys, hepatic bile duct proliferation and polydactyly, and the two conditions are known to be allelic at four loci[@R5]-[@R8]. The *MKS2* locus was initially mapped in families of North African and Middle Eastern ancestry to a chromosome 11q region telomeric to *JBTS2[@R9]*, but our subsequent identification of additional families, as well as SNP re-analysis of the initial family, indicated allelism with *JBTS2* between rs1113480 and rs953894 (48.014-62.518 Mb) ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Because JSRD and MKS are considered ciliopathies, of the 200 total candidate genes, we first sequenced the exons and splice sites of genes listed in the cilia proteome databases[@R10]-[@R11] in one affected subject from each *JBTS2/MKS2* family, but no mutations were identified.

Tetraspan transmembrane proteins are characterized by four hydrophobic, putative transmembrane domains (TM1-TM4), forming two extracellular and one intracellular loop, which regulate signaling and trafficking properties of their partner proteins in multiple cellular contexts[@R12]. While little is known about their function, they can act with Wnt receptors[@R13], and their ability to form complexes with a wide variety of membrane and cytosolic proteins[@R14] suggests that they may participate in the formation of membrane domains that regulate signaling and sorting processes. Transmembrane proteins also represented attractive candidates, due to similarities to *MKS3/TMEM67* encoding Meckelin, which is mutated both in JSRD and MKS[@R5],[@R15]. Therefore we additionally sequenced the eight genes encoding transmembrane proteins, eventually identifying homozygous deleterious mutations in *TMEM216* in six of the 12 JSRD/MKS families compatible with linkage to the locus ([Table 1](#T1){ref-type="table"}). Interestingly, residue p.R73 was mutated both in a Sicilian family with JSRD (COR000, p.R73L) and in a Turkish family, in which MKS and JSRD coexisted in the same sibship (COR114/F37, p.R73H). The p.G77A mutation in two Palestinian families (F56, F58) resulted from a substitution (c.230G\>C) that affects the first base of exon 5, leading to the use of an alternative splice site in intron 4, the inclusion of an additional 46bp and resultant premature protein termination (p.T78KfsX30) ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}**)**. None of these mutations were identified in over 500 controls from ethnically matched cohorts.

We next screened an additional 460 JSRD and 132 MKS probands (**[Supplementary Note](#SD1){ref-type="supplementary-material"}**) and identified mutations in 12 and two further cases, respectively ([Table 1](#T1){ref-type="table"}). Twelve of 14 JSRD families shared the same homozygous p.R73L founder mutation, including two families from Sicily and ten families of Ashkenazi Jewish descent. Saturation of the region surrounding the p.R73L mutation with 17 SNP/microsatellite markers indicated that these families shared the same ancestral haplotype, spanning 472 Kb around the mutation ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}**)**, that could be dated back at least 20 generations. The carrier frequency in the Ashkenazi population was determined to be about 1:100, as we identified two heterozygous healthy unrelated carrier individuals among a screened cohort of 212 Ashkenazi individuals, making carrier detection possible at least in this population. A similar carrier frequency of 1:92 has also been determined for the p.R73L mutation in a distinct study on eight Ashkenazi *JBTS2* families and 2766 unaffected controls[@R16]. Microsatellite analysis also detected shared haplotypes in the two Palestinian (F56, F58) and in the two Tunisian families (F2, F5), homozygous for the same mutations ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}).

Overall, 20 JSRD patients and 11 MKS fetuses carried *TMEM216* mutations ([Fig. 1b](#F1){ref-type="fig"}**,**​ [Table 1](#T1){ref-type="table"}). All of the nonsynonymous changes occurred in evolutionarily conserved residues ([Fig. 1c-d](#F1){ref-type="fig"}), and led to unstable protein when transfected into heterologous cells ([Fig. 1e](#F1){ref-type="fig"}**,**​ [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Although truncating mutations were identified in both the middle and end of the protein, p.R73 transversions predominated ([Fig. 1c](#F1){ref-type="fig"}), with the p.R73L clearly a founder mutation. Among JSRD, the phenotype was characterized by frequent occurrence of NPH (9/20) and polydactyly (9/20), while retinal dystrophy and congenital hepatic fibrosis were never observed. In keeping with this, sequence analysis of 96 patients with Bardet-Biedl syndrome identified no homozygous mutations, since retinopathy is a key feature of this condition. In two JSRD patients (MTI161 and MTI467), polydactyly was associated with either tongue tumors or multiple oral frenula, corresponding to the Oro-Facio-Digital type VI (or Varadi-Papp) syndrome[@R16] (OMIM%277170), indicating that *TMEM216* mutations are the first known identified cause. In the 11 MKS fetuses with *TMEM216* mutations, distinctive clinical features were skeletal dysplasia, including intrauterine growth retardation or bowing of the long bones in six fetuses, cleft palate in four, and anencephaly in two ([Table 1](#T1){ref-type="table"}**,**​ [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}).

*TMEM216* is a poorly annotated gene, with RefSeq predicting a protein of just 86 aa, suggesting potential alternative splicing. To characterize this mRNA we performed Northern analysis with a commercial human fetal blot, and found a single major mature isoform at about 1.4 Kb ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}), agreeing with the predicted 1.3 Kb of the longest representative cDNAs. To interrogate splicing we designed primers complementary to the furthest 5′ and 3′ regions of the known cDNA, and sequenced 48 cloned PCR products from a 20 week gestation human fetal brain library. We identified four major splice isoforms, the longest and most prevalent predicting a protein of 148 aa ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}), which we consider to be the full-length mRNA. There is also extensive alternative splicing, encoding very short proteins ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}), the functions of which were not evaluated further. Importantly, we did not find any mutations in any of the putative UTRs.

To elucidate roles for *TMEM216* in human development, we first examined its expression in human embryonic tissues. *In situ* hybridization analysis in human embryos confirmed expression in the central nervous system, limb bud, kidney and cartilage ([Supplementary Fig. 6c-h](#SD1){ref-type="supplementary-material"}), which is similar to the broad and relatively low-level expression pattern of other JSRD/MKS genes. We next raised an anti-TMEM216 polyclonal affinity-purified antibody against aa 81-90, demonstrated specificity ([Supplementary Fig. 7a-b](#SD1){ref-type="supplementary-material"}), and immunostained two different ciliated cell lines (inner medullary collecting duct \[IMCD3\] and retinal pigment epithelium \[hRPE\]). We observed localization with the base of the primary cilium or adjacent basal body in the majority of cells, as marked by either acetylated or glutamylated tubulin staining ([Fig. 2a-d](#F2){ref-type="fig"}). TMEM216 antibody also reacted strongly to the base of cilia in organs like kidney containing ciliated cells ([Fig. 2c](#F2){ref-type="fig"}**,**​ [Supplementary Fig. 7c](#SD1){ref-type="supplementary-material"}), but failed to react with these structures in hTERT-immortalized fetal *TMEM216* p.R85X homozygous mutant fibroblasts ([Supplementary Fig. 7d](#SD1){ref-type="supplementary-material"}**)**. Epitope-tagged TMEM216 showed similar localization to the base of cilia and other microtubule structures (i.e. mitotic spindle in cells undergoing late telophase, [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}).

In *TMEM216* p.R85X mutant fibroblasts, we noticed a failure in ciliogenesis following 48 hr serum starvation ([Fig. 3a](#F3){ref-type="fig"}) compared with controls. Western analysis of whole cell lysates from control fibroblasts identified a band at 19 kD ([Fig. 3b](#F3){ref-type="fig"}), matching the predicted 148 aa full length protein, whereas this band was attenuated or lost in *TMEM216* p.R85X fibroblasts or in IMCD3 cells in which *Tmem216* was knockded down.

To determine the basis of the ciliogenesis defect, we performed transient transfection of monolayers of IMCD3 cells with two separate *Tmem216* siRNA duplexes*. Tmem216* knockdown prevented ciliogenesis in polarized cells, and blocked correct docking of centrosomes at the apical cell surface ([Fig. 3c](#F3){ref-type="fig"}), as seen previously for Meckelin and MKS1[@R17]. This ciliogenesis defect was quantified by comparing the percentage of cells with cilia (defined as \> 1 μm length) vs. those without cilia (\< 1μm length), and by analyzing the percentage of cells with centrosomes located apical to the nucleus. In cells in which *Tmem216* was knocked down, we observed a striking defect in both of these measurements compared with two separate control transfections ([Fig. 3d-e](#F3){ref-type="fig"}**,** chi-squared test, p\<0.001, for 350 cells from each condition), suggesting its requirement in centrosome docking.

The similarities in cellular phenotypes of *Mks3* and *Tmem216* knockdown, and subcellular localizations of Meckelin and TMEM216, prompted us to ask if the two proteins could interact. Firstly, GFP-tagged TMEM216 was immunoprecipitated with antibodies to either N- or C-terminal portions of Meckelin ([Fig. 4a](#F4){ref-type="fig"}) and, secondly, the reciprocal IP experiment used α-GFP antibody to pull down Meckelin ([Fig. 4b](#F4){ref-type="fig"}). Both assays detected a complex between TMEM216 and Meckelin.

Many aspects of actin-dependent polarized cell behavior, including morphogenetic cell movements[@R18] and ciliogenesis[@R19], are mediated by the planar cell polarity (PCP) pathway of non-canonical Wnt signaling[@R20]. We therefore first examined RhoA, since the Rho family of small GTPases are key mediators of this pathway[@R20]-[@R21]. Consistent with previous results following *MKS3* loss[@R22], we found that RhoA signaling was hyperactived in both *TMEM216* p.R85X fibroblasts or following *Tmem216* knockdown ([Fig. 4c-d](#F4){ref-type="fig"}), despite normal total amounts of RhoA in these cells. Centrosome docking at the apical cell surface is prevented by the interruption of actin remodeling[@R23], and is dependent on both RhoA activation and regulation by the core PCP protein Dishevelled (Dvl)[@R24]. We confirmed that RhoA is localized to the basal body in confluent IMCD3 cells but, following *Tmem216* knockdown for 24 hr, RhoA was mislocalized to peripheral regions of the basal body and to basolateral cell-cell contacts ([Fig. 4e](#F4){ref-type="fig"}), consistent with translocation of ectopically-activated RhoA to the cytosol[@R25]. *Tmem216* knockdown also showed evidence of a mislocalization of γ-tubulin at the centrosome/basal body for this timepoint, which suggests a defect in γ-tubulin nucleation, one of the earliest steps in ciliogenesis[@R26]. The established role of RhoA in modulating the actin cytoskeleton in the PCP pathway then led us to evaluate *MKS2* patient fibroblast lines for alterations. We found a co-localization of actin stress fibers and the actin cross-linker filamin-A in the cytoplasm of these mutant cells, which was absent in control ([Fig. 4f](#F4){ref-type="fig"}).

We next looked at Dvl signaling in cells, since cilia negatively regulate Dvl activation[@R27], and Dvl mediates Rho activation at the apical surface of ciliated epithelial cells[@R24]. We found that loss of TMEM216 increased phosphorylation of Dvl1 ([Fig. 5a](#F5){ref-type="fig"}​ **left and right panel**), implying that TMEM216 modulates hyper-responsiveness of signaling pathways mediated by Dvl and RhoA. We found that Rho inhibition also increased the Dvl1 phosphorylation in ciliated cells, supporting the existence of feedback mechanism between Rho and Dvl ([Fig. 5a](#F5){ref-type="fig"}**, right panel)**. Unexpectedly, the constitutive Dvl1 phosphorylation associated with TMEM216 loss was blocked by Rho inhibition ([Fig. 5a](#F5){ref-type="fig"}**, right panel**), suggesting that this loss in ciliated cells can modify the feedback mechanism. Although this possibility warrants further investigation, our data nevertheless suggest a working model in which Dvl1, RhoA and TMEM216 may serve as part of a complex in the pericentrosomal compartment to mediate cellular polarization and centrosomal apical docking. Previous studies have shown that Dvl and Rho contribute to a core framework for regulating the apical docking of centrosomes[@R24], and we also see evidence of a common complex containing TMEM216, Dvl1 and RhoA in TMEM216-transfected cells ([Fig. 5b](#F5){ref-type="fig"}). Since we saw no difference in the localization of Dvl1 following *Tmem216* knockdown **(**[Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}), these data predict that the hyperactivation of Rho in the absence of TMEM216 might be responsible for the centrosome docking defect at the apical cellular surface. As expected, we found that the impaired centrosome docking caused by *Tmem216* knockdown was rescued in a dose-dependent fashion using Rho inhibitor ([Fig. 5c](#F5){ref-type="fig"}).

Meckelin is proposed to regulate centrosomal docking through the RhoA signaling pathway[@R22], and bears similarity to the Frizzled family of transmembrane Wnt receptors[@R15]. Direct evidence of a role for Meckelin in PCP signaling stems from zebrafish embryo morphant phenotypes following morpholino knock-down of *mks3[@R28]*. These included defects in gastrulation movement (a shortened body axis, broad notochords and misshapen somites), which are typical of defects in non-canonical (PCP) Wnt signaling, and have been observed in numerous ciliary and basal body morphants[@R28]-[@R29]. We observed identical ciliary phenotypes in *tmem216* morphants, which were largely rescued by RNA encoding human *TMEM216* ([Fig. 5d](#F5){ref-type="fig"}), and fully rescued by RNA encoding non-targetable zebrafish *tmem216* (not shown). We therefore directly compared the *tmem216* and *mks3* morphant phenotypes in zebrafish, and noted similar defects in both live embryos and in embryros in which pronephric mesoderm, anterior neural structures, adaxial mesodermal cells, and somites were labeled with a *krox20, pax2*, and *myoD* riboprobe cocktail ([Fig. 5e-f](#F5){ref-type="fig"}). Quantification demonstrated alteration of convergence to the midline and extension along the AP axis consistent with a PCP defect, although the AP extension defect was more pronounced in the *mks3* compared to the *tmem216* morphant.

Recent work has implicated the tetraspanin TSPAN12 in the regulation of Norrin signaling by the Wnt receptor Frizzled-4 and coreceptor LRP5[@R13]. We therefore speculate that TMEM216, a novel tetraspan protein, forms a non-canonical Wnt receptor-coreceptor complex with Meckelin. Our data support a role for both proteins in mediating PCP signaling through the RhoA pathway to cause actin cytoskeleton rearrangements, although whether Rho functions upstream or downstream of Dvl1 remains to be determined. In apical regions of the cell, such actin reorganization would be an essential step before the centrosome/basal body could dock correctly and initiate ciliogenesis. The identification of mutations in *TMEM216* as a cause of JSRD and MKS therefore further emphasizes the interrelationship between cell polarity, cellular morphogenesis and signal transduction pathways.
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ONLINE METHODS {#S2}
==============

Research subjects {#S3}
-----------------

We used standard methods to isolate genomic DNA from peripheral blood of the affected children and family members or from frozen fetal tissue or amniocytes. Chromosome analysis was performed for at least one patient of each family. Informed consent was obtained from all participating families and the studies were approved by the Ethics Boards of Leeds (East), Casa Sollievo della Sofferenza, Hôpital Necker-Enfants Malades, and UCSD.

Genetic mapping {#S4}
---------------

To refine the *MKS2/JBTS2* locus, the 10K Affymetrix SNP array was used to perform a genome-wide linkage search in nine consanguineous families with MKS. We performed multipoint linkage analysis using MERLIN software, assuming a fully penetrant recessive model, a disease allele frequency of 0.001, and allowed for heterogeneity between families. Areas of homozygosity on chromosome 11 were confirmed by performing high-resolution haplotype analysis.

Mutation screening {#S5}
------------------

Mutational screening of *TMEM216* was performed by direct sequencing of PCR products of the six coding exons and the adjacent intronic junctions in JSRD/MKS families showing potential linkage to the locus and all MKS cases. To test for *TMEM216* mutations in the cohort of 460 JSRD patients we applied the high resolution melting (HRM) technique[@R30] using a LightCycler 480 (Roche Applied Science), with the same primers and optimized PCR conditions ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Segregation of the identified mutations was investigated in all available family members. Missense mutations were excluded in the following ethnically matched controls: wildtype at p.R73 for 227 Italian and 109 Turkish; and wildtype at p.G77 and p.L114 for 158 Palestinian and 112 Tunisian individuals. All mutations were also excluded in 200 Central Asian (predominantly Pakistani), 200 European (predominantly British), as well as a cohort of 96 ethnically diverse individuals.

Founder haplotype analysis {#S6}
--------------------------

The region surrounding *TMEM216* was saturated with 14 single nucleotide polymorphisms and three microsatellite markers in ten patients homozygous for the same p.R73L mutation. Estimation of the mutation age was calculated as reported[@R31].

Bioinformatics {#S7}
--------------

Genetic location is based on Human Genome Browser build 36.3 (<http://www.genome.ucsc.edu>). The ciliary proteome was searched using web-based tools[@R10]-[@R11]. RefSeq and Pfam were respectively accessed at (<http://www.ncbi.nlm.nih.gov/RefSeq/>) and (<http://pfam.sanger.ac.uk/>).

Cloning {#S8}
-------

Full-length *TMEM216* was cloned into the pcDNA3.0 vector, and then shuttled into the mCherry-, EGFP-, and FLAG- containing vectors. Mutations were introduced into TMEM216-pEGFP-N3 by QuickChange mutagenesis (Stratagene). *TMEM216* open reading frame was also cloned into pCS2+ vector in order to make RNA for injection into zebrafish embryos.

Cells and antibodies {#S9}
--------------------

Mouse inner medullary collecting duct (IMCD3), human hTERT-immortalized retinal pigmentary epithelial (hRPE), and human embryonic kidney (HEK293) cells were grown in Dulbecco's minimum essential medium (DMEM)/Ham's F12 supplemented with 10% fetal calf serum at 37°C/5% CO~2~. Fibroblasts were immortalized with the hTERT system, and maintained in Fibroblast Growth Medium (Genlantis) supplemented with 10% fetal calf serum and 0.2 mg/ml geneticin. Normal, undiseased control fibroblasts were gestationally-age matched to fibroblasts from MKS patients[@R22]. Primary antibodies used were: mouse α-EGFP antibody (Covance MMS-118R); mouse anti-GFP and rabbit A.V. peptide ("Living Colors", Clontech); mouse anti-α-tubulin, mouse anti-γ-tubulin, mouse anti-acetylated-tubulin (Sigma-Aldrich); mouse-anti-glutamylated tubulin (GT335)[@R32], rabbit-anti-γ-tubulin, rabbit-anti-Meckelin, mouse anti-β actin (Abcam); mouse anti-filamin A (AbNova); and mouse anti-Dvl1 (Santa Cruz Biotechnology SC-8025); mouse anti-RhoA (Cytoskeleton). Rabbit-anti-Meckelin C-terminus, raised against amino acids 982-995, has been described previously[@R17]. Rabbit-anti-Meckelin N-terminus, raised against amino acids 100-113, has also been described[@R22]. Secondary antibodies were Alexa-Fluor 488-Alexa-Fluor 594- and Alexa-Fluor 568-conjugated goat anti-mouse IgG and goat anti-rabbit IgG (Molecular Probes), and HRP-conjugated goat anti-mouse and goat anti-rabbit (Dako). Alexa-Fluor 488 and 633 phalloidin conjugate (Molecular Probes) was used to visualize F-actin.

Biochemical assays {#S10}
------------------

Constructs encoding wildtype or mutant TMEM216 were transfected into 293T cells in a ratio of 20:1 TMEM216:TK-βgal vector. Cells were lysed after 48h and samples analyzed by Western blot with α-EGFP antibody (1:500) and β-gal assay to standardize transfection efficiency[@R33]. Normalized loading levels were confirmed by blotting with α-tubulin (1:2000).

Rabbit-anti-TMEM216 antiserum was raised against the peptide sequence NLCQRKMPLS(C), comprising amino acids 81-90, by GenScript (Piscataway, NJ, USA). Antiserum was affinity-purified, and co-immunoprecipitation was performed as described previously[@R34]. Whole cell extracts (WCE) were prepared from confluent untransfected HEK293 cells, or IMCD3 cells that had been transiently transfected with 1.0 μg plasmid constructs in 90mm tissue culture dishes, or scaled down as appropriate. WCE supernatants were processed for immunoprecipitation experiments by using 5 μg affinity-purified mouse anti-GFP, or 5 μg MAbs, or 5-10 μg purified IgG fractions from rabbit polyclonal antisera, coupled to protein G- and/or protein A-sepharose beads (GE Healthcare) Immunoprecipitations were performed in reduced salt incubation buffer (20 mM Tris, pH7.5, 25 mM NaCl, 2 mM EDTA, 0.5 mM EGTA, 0.02% \[w/v\] NaN3, 10% \[v/v\] glycerol, 10% \[v/v\] ethanol, 0.1% \[v/v\] protease inhibitor cocktail). For assessing Dvl1 phosphorylation status, extraction and wash buffers were supplemented with phosphatase inhibitor cocktail (Sigma Aldrich).

*In situ* hybridization in human embryos {#S11}
----------------------------------------

Human embryos were collected from terminated pregnancies using the mefiprestone protocol in agreement with French bioethics laws (94-654 and 04-800). Embryos were fixed in 11% formaldehyde, 60% ethanol and 10% acetic acid, embedded in paraffin and sectioned at 5 μm. Primers ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) were selected for RT-PCR amplification on RNA extracted from a whole C12 (4w) embryo to be used as template for generating the riboprobes, as described previously[@R35]. Sections were hybridized with a Digoxygenin labeled probe at 70°C overnight, and digoxygenin was detected with an anti-DIG-Fab' antibody (Roche) at 1:1000.

Immunofluorescence and confocal microscopy {#S12}
------------------------------------------

IMCD3 or hTERT-immortalized fetal fibroblasts were seeded at 20 × 10^3^ cells/well on glass coverslips in six-well plates and fixed in ice-cold methanol (5 minutes at 4°C) or 2% paraformaldehyde (20 minutes at room-temp) as described previously[@R17],[@R22]. Confocal images were obtained using a Nikon Eclipse TE2000-E system, controlled by EZ-C1 3.50 (Nikon) software. Images were processed in Metamorph, and figures were assembled using Adobe Photoshop CS3.

Transfection and siRNA {#S13}
----------------------

For transfection with plasmids, cells at 90% confluency were transfected using Lipofectamine 2000 (Invitrogen). Cells were incubated for 24 to 72 hrs prior to lysis or immunostaining. For RNAi knockdown in IMCD3 cells, siRNA duplexes ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) were designed against different regions of the mouse *Tmem216* ("Stealth Select", Invitrogen). *Mks3* siRNA reagents have been described previously[@R22]. The medium or low GC non-targeting negative controls (Invitrogen) were used as scrambled siRNA controls. Irrelevant siRNA duplexes against *Hhari* were used as a second negative control (a gift from P. Robinson, University of Leeds, UK). Individual duplexes (20 nM) or siRNA pools (total 60 nM) were transfected into IMCD3 cells at 60-80% confluency using Lipofectamine 2000 RNAiMAX (Invitrogen). The efficiency of siRNA transfections, as determined with BLOCK-iT Fluorescent Oligo (Invitrogen), was \>60%. Further assays were carried out at 72 hours after transfection.

Gene expression analyses with quantitative real-time PCR {#S14}
--------------------------------------------------------

For the relative quantitation of gene expression we used quantitative real-time PCR for the standard curve method. Total RNA (1 μg) was reverse-transcribed using the Superscript III first strand cDNA system (Applied Biosystems). PCR analysis of cDNA was performed using dHPLC-purified primers ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) specific for mouse Tmem216 (Invitrogen), following optimization to eliminate primer-dimers and subsequent confirmation by analysis of amplimer dissociation curves following a qPCR run. Each reaction was run in triplicate. Amplimer levels were quantified continuously with the SYBR GreenER qPCR system (Invitrogen) using an ABI 7500 instrument, essentially as described previously[@R15]. *Hprt* RNA was amplified for normalization, quantified in [Supplementary Figure 10](#SD1){ref-type="supplementary-material"}.

RhoA activation assay {#S15}
---------------------

The activated GTP-bound isoform of RhoA was specifically assayed in pull-down assays using a GST fusion protein of the Rho effector rhotekin (Cytoskeleton), using conditions recommended by the manufacturers. Rho activity was inhibited by treating cells with cell permeable exoenzyme-C3-transferase (Cytoskeleton) at 2 μg/ml for 5 hr under standard cell culture conditions. Results shown are representative of three separate experiments. Full scans of all Western blots are shown in [Supplementary Figure 11](#SD1){ref-type="supplementary-material"}.

Identification of ciliary defect phenotypes in Zebrafish {#S16}
--------------------------------------------------------

To knockdown *tmem*216 in zebrafish, a translational blocking morpholino antisense oligonucleotide (MO) or control (Gene Tools) or control was microinjected (4ng/nl) into one-two cell stage embryos, obtained from natural spawning of wild-type (AB) zebrafish lines. The mRNA encoding full-length human *TMEM216* was co-injected where indicated. Endogenous *mks3* was suppressed with a splice-blocking MO described previously (3 ng/nl)[@R28]. For assessment of gastrulation phenotypes (shortened body axis, wide undulating notochord, thin and elongated somites, and small anterior structures), mid-somitic embryos were scored blind at 8 somites (live; 80-100 embryos/injection), or 10-11 somites (morphometric analyses). Embryos were fixed overnight in 4% PFA, hybridized *in situ* with DIG-labeled *krox20, pax2*, and *myoD* riboprobes according to standard protocols, and flat-mounted for imaging and analysis. At 3 days postfertilization, morphological phenotype of morphants were quantified under bright-field microscopy based upon ciliary defects (hydrocephalus, small brain, heart edema, and curved tail) or embryonic lethal phenotypes.

![Mutations in the *TMEM216* gene in patients linked to the *JBTS2* and *MKS2* loci. **(a)** Chromosomal location of the *JBTS2* and *MKS2* loci on Chr. 11cent. (**b**) *TMEM216* genomic organization, depicting start and stop codon, and location of identified base changes. **(c)** The longest splice isoform encodes for a 148 aa tetraspan membrane protein. Patient mutations predominate towards the middle, with one prevalent p.R73 change occurring repeatedly. Missense, nonsense and splice mutations were identified. **(d)** Evolutionary conservation of mutated amino acids. **(e)** Patient mutations lead to unstable protein products. Western blot of whole lysate of cells transfected with a cDNA encoding wild type (WT) vs. patient missense mutations, compared with control (p.V71L). Each mutation resulted in the production of 40-50% of WT protein levels, compared with α-tubulin loading control.](ukmss-30246-f0001){#F1}

![Ciliary localization of TMEM216. (**a-d**) Overlapping localization of endogenous TMEM216 (green) and acetylated α-tubulin or GT335 (glutamylated tubulin) (red) at the base of the primary cilium (arrows) in IMCD3 (a, b), proximal renal tubules (c) or hRPE cells (d). White dashed line indicates the tubule lumen. Boxes show insets at magnification x10. Scale bar 5 μm.](ukmss-30246-f0002){#F2}

![*TMEM216* mutation or knockdown results in impaired ciliogenesis and centrosome docking. **(a)** Two different *TMEM216*-mutated patient fibroblasts lines show defective ciliogenesis and impaired centrosome docking (marked by γ-tubulin). Scale bar: left 20 μm; right 1 μm. **(b)** TMEM216 antisera reacts with a 19 kDa band in control cells, which is reduced in *TMEM216* p.R85X fibroblasts (some residual is apparent likely due to read-through from geneticin treatment), as well as in siRNA1-treated IMCD3 cells. Fibro. = fibroblasts; Non-transf. = non-transfected; scr. = scrambled. **(c)** Transfected IMCD3 cells showing effect of *Tmem216* siRNA treatment, with reduced ciliogenesis and centrosome docking (note lack of cilia and lack of apically located centrosomes following knockdown). Top is *x-y*, and bottom is *x-z* projection, scale bar 10 μm. **(d)** Percent ciliated cells (defined as cilia \> 1 μm length) is reduced following *Tmem216* siRNA treatment. Percent cells with apical basal bodies (defined as most superior 1.0 μm sections compared to nuclear position) is similarly reduced. \*p\<0.01, \*\*p\<0.001, chi-squared test. (**e**) Shows method of quantification at 72 hrs. Scale bars: white, most apical 1.0 μm; grey, basal 1.5 μm.](ukmss-30246-f0003){#F3}

![TMEM216 complexes with Meckelin, and their loss results in Rho hyperactivation and actin cytoskeleton remodelling. **(a)** TMEM216-GFP (\~37 kDa; arrow) is immunoprecipitated (IP) with anti-Meckelin antisera against either the N- or C-termini from whole cell extract (input WCE), but not in control IPs with an irrelevant antibody (irr. Ab) or the preimmune antiserum (preimm.). Arrowhead is IgG heavy chain. **(b)** IP of TMEM216-GFP by α-GFP pulls down a 60 kDa C-terminal containing isoform of endogenous Meckelin (arrow), but not in control IPs with no antibody (no MAb) or an irrelevant antibody (irr. MAb). Arrowhead is IgG heavy chain. **(c)** MKS2 fibroblast (fibro.) WCE has increased levels of activated RhoA-GTP compared to normal control. **(d)** siRNA knockdown of *Tmem216* and *Mks3* in IMCD3 cells increased RhoA activation, compared with scrambled control (scr.). Total RhoA and β-actin are loading controls. Positive control (+) is loading with non-hydrolyzable GTPγS, negative control (−) is loading with GDP. **(e)** RhoA (red) localizes to the basal bodies (γ-tubulin, green) in IMCD3 cells following 24 hr treatment with scrambled siRNA, but mislocalizes to regions adjacent to the basal bodies (arrows; and inset, magnification x5) and at basolateral surfaces (arrowheads) following *Tmem216* knockdown. Mislocalization of γ-tubulin is also apparent (bottom inset). Scale bar 10 μm. **(f)** Subcellular phenotypes of fibroblasts cultured from undiseased control and two MKS fetuses mutated in *TMEM216* \[p.R85X homozygous\] and *MKS3* \[p.R217X\]+\[p.M261T\], as indicated. Actin stress fibers in both mutated cells (arrowheads) are detected by phalloidin staining. Scale bar 10 μm.](ukmss-30246-f0004){#F4}

![TMEM216 disruption results in Dvl1 phosphorylation, and planar cell polarity-like phenotypes in zebrafish. **(a)** siRNA knockdown of *Tmem216* (*left panel*) and *TMEM216* p.R85X patient fibroblasts (*right panel*) cause an increase in the upper (phosphorylated) isoform (P-Dvl1) compared to scrambled control (scr.). Treatment with Rho inhibitor exoenzyme-C3-transferase (2 μg/ml) alone increased Dvl1 phosphorylation, but increases in P-Dvl1 by TMEM216 loss are reversed by Rho inhibition (*right panel*). **(b)** Co-immunoprecipitation of both Dvl1 and RhoA with TMEM216 in TMEM216-GFP transfected cells. Arrowhead is IgG heavy chain. **(c)** Dose-dependent rescue of centrosome/basal body docking phenotype in *Tmem216* siRNA-treated cells following += 0.5, ++= 1.0, +++= 2.0 μg/ml Rho inhibitor treatment. \*p\<0.01; \*\*p\<0.001 for chi-squared test. **(d)** Injection of translation-blocking morpholino (MO) to *tmem216* vs. scrambled MO causes a ciliary defect phenotype in injected zebrafish embryos (\>50 each condition). Injection of human *TMEM216* RNA causes no phenotype in WT embryos, but allows partial, dose-dependent rescue of the MO phenotype. **(e)** Lateral (top) and dorsal (bottom) views of zebrafish embryos injected with *tmem216* or *mks3* MO at 8-somite stage had ciliopathy features. **(f)** Representative 11-somite stage embryos hybridized with *krox20, pax2,* and *myoD* riboprobes. Convergence to the midline is measured by the width at the fifth rhombomere (horizontal arrow), and extension along the anterior-posterior (AP) axis by notochord length (vertical arrow) (n=12-15 embryos/injection). Suppression of the *tmem216* or *mks3* morphant gastrulation defect causes significant differences in width and length compared to controls (\*p\<0.005). Pheno.=phenotype; embry.=embryonic; rhomb.=rhombomere; Bars=standard error of means.](ukmss-30246-f0005){#F5}

###### Clinical and molecular data of *TMEM216* mutated families

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family data                                Clinical data                 Genetic data                                                                              
  ------------------------------------------ ----------------------------- -------------- ---------- ---------- ---------- ----- ---------------------- ------------ -----------------
  ***Joubert syndrome related disorders***                                                                                                                           

  COR000                                     11y, M 15y, F 20y, F 29y, M   Italian        MTS        \-         NPH        ELE   \-                     c.218G\>T    p.R73L

  15y, F                                     MTS                           \-             NPH        \-         \-                                                   

  20y, F                                     MTS                           \-             NPH        \-         \-                                                   

  29y, M                                     MTS                           \-             NPH        \-         \-                                                   

                                                                                                                                                                     

  COR284                                     22y, F                        Italian        MTS                   NPH                                     c.218G\>T    p.R73L

                                                                                                                                                                     

  COR114/\                                   1m, M                         Turkish        MTS        MicroC                      PD                     c.218G\>A    p.R73H
  F37                                                                                                                                                                

  13w, M[\*](#TFN1){ref-type="table-fn"}     Ec                            CK             BDP        PD, BLB                                                         

                                                                                                                                                                     

  F401                                                                     New Zealand    MTS        \+         NPH                                     c.217C\>T\   p.R73C\
                                                                                                                                                        c.398T\>G    p.L133X

                                                                                                                                                                     

  COR076                                     1y, F\                        Ashk           MTS, PMG   \-                          ToF                    c.218G\>T    p.R73L
                                             fetus                                                                                                                   

                                                                                                                                                                     

  COR287                                     3m, M                         Ashk           MTS                                    PD                     c.218G\>T    p.R73L

                                                                                                                                                                     

  MTI005                                     13y, M                        Euro           MTS        OMA        NPH?       \-    CD                     c.218G\>T    p.R73L

  3y, F                                      MTS                           OMA                       \-         CD                                                   

                                                                                                                                                                     

  MTI161                                     4y, M                         Ashk           MTS        OMA, Nys   \-         \-    PD, TT, MP             c.218G\>T    p.R73L

                                                                                                                                                                     

  MTI214                                     4y, F                         Ashk           MTS        OMA        \-         \-    CMD                    c.218G\>;T   p.R73L

                                                                                                                                                                     

  MTI467                                     fetus                         Ashk           MTS, DWM              \-         \-    PD, MOF,\              c.218G\>;T   p.R73L
                                                                                                                                 CD, HYPT                            

                                                                                                                                                                     

  MTI585                                     1y, F                         Ashk           MTS        Co         ACMD       \-    CMD                    c.218G\>;T   p.R73L

                                                                                                                                                                     

  MTI658                                     8y, F                         Ashk           MTS        Nys        NPH?       \-    PD, CMD                c.218G\>;T   p.R73L

  5y, F                                      MTS                           Nys            NPH?       \-         PD, CMD                                              

  2 fetuses                                                                                                                PD                                        

                                                                                                                                                                     

  MTI1006                                    9y, M                         Ashk           MTS        OMA, Nys   \-         \-    \-                     c.218G\>;T   p.R73L

  1y, M (cousin)                             MTS                           OMA, Nys       \-         \-         PD                                                   

                                                                                                                                                                     

  MTI1008                                    4y, F                         Ashk           MTS, DWM   OMA                         RTP                    c.218G\>;T   p.R73L

                                                                                                                                                                     

  ***Meckel syndrome***                                                                                                                                              

  F2                                         21w, M                        Tunisian       Mc                    CK         BDP   PD, CP, BLB            c.341T\>G    p.L114R

  14w, F                                     An                                           CK         BDP        PD, BLB                                              

                                                                                                                                                                     

  F5                                         24w, M                        Tunisian       Mc         MicroO     CK         BDP   PD, CP, IUGR,\         c.341T\>G    p.L114R
                                                                                                                                 BLB, HypoG                          

                                                                                                                                                                     

  F56                                        fetus                         Palestinian    An                    CK                                      c.230G\>C    p.G77A→splice:\
                                                                                                                                                                     p.T78KfsX30

  15w                                        DW, Ec                                       CK                    IUGR                                                 

                                                                                                                                                                     

  F58                                        SB, M                         Palestinian    Ec                    CK         BDP   PD, CP                 c.230G\>C    p.G77A→splice:\
                                                                                                                                                                     p.T78KfsX30

  1day                                       Ec                                           CK         BDP        PD                                                   

                                                                                                                                                                     

  F154                                       22w SB                        Palestinian    Mc                    CK                                      c.230G\>C    p.G77A→splice:\
                                                                                                                                                                     p.T78KfsX30

                                                                                                                                                                     

  A2423                                      21w, M                        British        Ec                    CK         BDP   PD, CP, VSD, IM, BLB   c.253C\>T    p.R85X

  12w, M                                     Ec                                           CK         \-         CH, Omph                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Legend:** -: not affected; ACMD: abnormal cortico-medullary differentiation; An: anencephaly; Ashk: Ashkenazi Jewish; BDP: bile ducts proliferation; BLB: bowing of long bones; CD: clinodactyly; CH: cystic hygroma; CK: cystic kidneys; CMD: camptodactyly; Co: chorioretinal coloboma; CP: cleft palate; CVA: cerebellar vermis agenesis; DW: Dandy-Walker malformation; Ec: encephalocele; ELE: elevated liver enzymes; Euro: European; F: female; HypoG: hypoplastic external genitalia; HYPT: hypertelorism; IM: intestinal malrotation; IUGR: intrauterine growth retardation; M: male; m: months; IUGR: intrauterine growth retardation; Mc: meningocele; MEc: meningoencephalocele; MOF: multiple oral frenulae; MicroC: microcornea; MicroO: microphthalmia; MP: micropenis; MTS: molar tooth sign; NPH: nephronophthisis; Nys: nystagmus; OMA: oculomotor apraxia; Omph: omphalocele; PD: polydactyly; PMG: polymicrogyria; RTP: rhythmic tongue protrusions; SB: stillbirth; ToF: tetralogy of Fallot; TT: tongue tumors; VSD: ventricular septal defect; w: gestational weeks; y: years. Empty cells denote unavailable clinical information;

MKS fetus.
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